The combination of ibrutinib with chemoimmunotherapy improved the duration of response for a subset of patients with relapsed follicular lymphoma and marginal zone lymphoma.
Morgan Bayer
Morgan Bayer is an assistant editor for Targeted Oncology and Targeted Therapies in Oncology.
Articles by Morgan Bayer
The FDA plans to conduct a speedy review of the supplemental new drug application for ivosidenib tablets as treatment of IDH1-positive, relapsed or refractory myelodysplastic syndrome.